Premium
A PILOT STUDY OF ORALLY ADMINISTERED Δ 1 ‐TRANS‐TETRAHYDROCANNABINOL IN THE MANAGEMENT OF PATIENTS UNDERGOING RADIOTHERAPY FOR CARCINOMA OF THE BRONCHUS
Author(s) -
DAVIES B.H.,
WEATHERSTONE R.M.,
GRAHAM J.D.P.,
GRIFFITHS R.D.
Publication year - 1974
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1974.tb00257.x
Subject(s) - carcinoma , medicine , radiation therapy , bronchus , tetrahydrocannabinol , oncology , pharmacology , surgery , respiratory disease , lung , cannabinoid , receptor
1 Δ 1 ‐ trans ‐tetrahydrocannabinol (Δ 1 ‐THC; 10 mg) or a placebo was given orally on 7 days to two groups of six patients on a cross‐over pattern with 7 days rest between. 2 The patients were hospitalized, suffering from inoperable bronchogenic carcinoma, subjected to radiation therapy, and anxious. 3 Self‐rating mood scales were filled in before, and 2 and 6 h after ingestion on the first and seventh day of medication. 4 Records of sleep, pain, general well‐being, temperature, cardiovascular and gastrointestinal parameters were kept. 5 Δ 1 ‐THC caused drowsiness and improved night sleep, reduced pain, increased fatigue and confusion and reduced elation and vigour; it caused slight tachycardia and hypotension as also did placebo. 6 The effects of Δ 1 ‐THC were stronger after 2 h than 6 h and no tolerance had developed at 7 days. 7 The management of stressful patients was considered to have been improved by the drug.